ReWalk Robotics Ltd. (NASDAQ:LFWD) Short Interest Update

ReWalk Robotics Ltd. (NASDAQ:LFWD) was the target of a large growth in short interest in December. As of December 31st, there was short interest totalling 222,600 shares, a growth of 21.4% from the December 15th total of 183,400 shares. Currently, 3.0% of the shares of the stock are short sold. Based on an average daily volume of 214,800 shares, the days-to-cover ratio is presently 1.0 days.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reissued a “buy” rating and issued a $13.00 price target on shares of ReWalk Robotics in a research note on Wednesday, November 13th.

ReWalk Robotics Price Performance

NASDAQ LFWD traded down $0.17 during trading hours on Friday, hitting $1.64. The company had a trading volume of 397,626 shares, compared to its average volume of 1,101,389. The firm’s 50 day moving average is $1.88 and its 200 day moving average is $2.80. ReWalk Robotics has a fifty-two week low of $1.41 and a fifty-two week high of $7.84. The company has a market capitalization of $14.45 million, a price-to-earnings ratio of -0.66 and a beta of 2.08.

ReWalk Robotics (NASDAQ:LFWD) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.35) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.08). ReWalk Robotics had a negative net margin of 77.21% and a negative return on equity of 43.02%. The firm had revenue of $6.13 million for the quarter, compared to analyst estimates of $8.38 million. During the same period in the previous year, the business posted ($0.56) earnings per share. On average, equities analysts anticipate that ReWalk Robotics will post -1.78 EPS for the current year.

Insider Activity

In other ReWalk Robotics news, Director Michael Swinford bought 16,471 shares of the business’s stock in a transaction on Wednesday, November 20th. The stock was bought at an average price of $1.84 per share, for a total transaction of $30,306.64. Following the completion of the transaction, the director now owns 26,511 shares in the company, valued at approximately $48,780.24. The trade was a 164.05 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, major shareholder Global Fund Lp Lind II sold 381,676 shares of ReWalk Robotics stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $3.36, for a total value of $1,282,431.36. Following the transaction, the insider now owns 1,049,430 shares of the company’s stock, valued at $3,526,084.80. This represents a 26.67 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders purchased 61,000 shares of company stock worth $115,279 in the last 90 days. 2.50% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On ReWalk Robotics

A hedge fund recently bought a new stake in ReWalk Robotics stock. Dimensional Fund Advisors LP acquired a new stake in ReWalk Robotics Ltd. (NASDAQ:LFWD) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm acquired 13,548 shares of the company’s stock, valued at approximately $54,000. Dimensional Fund Advisors LP owned about 0.16% of ReWalk Robotics as of its most recent SEC filing. Hedge funds and other institutional investors own 26.76% of the company’s stock.

ReWalk Robotics Company Profile

ReWalk Robotics Ltd., a medical device company, designs, develops, and commercializes technologies that enable mobility and wellness in rehabilitation and daily life for individuals with physical and neurological conditions in the United States, Europe, the Asia-Pacific, and internationally. It offers ReWalk personal exoskeleton and rehabilitation exoskeleton devices; ReStore, a soft exo-suit intended for use in the rehabilitation of individuals with lower limb disability due to stroke; AlterG Anti-Gravity System for use in physical and neurological rehabilitation and athletic training; MyoCycle devices; and ReBoot, a personal soft exo-suit for home and community use by individuals post-stroke.